

Aldurazyme (laronidase)

Drugs **ALDURAZYME**

Covered Uses

All FDA-approved indications not otherwise excluded from Part D.

Exclusion Criteria

Required Medical Information

Documented diagnosis of Mucopolysaccharidosis I (Hurler, Hurler-Scheie, or Scheie form) confirmed by and Enzyme assay demonstrating deficiency of alpha-L-iduronidase activity or DNA testing AND dose does not exceed 0.58 mg/kg/week.

Age Restriction

Greater than or equal to 6 months

Prescriber Restriction

Coverage Duration

Plan Year

Other Criteria

Drugs
ALHEMO

Covered Uses

All FDA-approved indications not otherwise excluded from Part D.

Exclusion Criteria

Required Medical Information

Diagnosis of Hemophilia A or Hemophilia B

Age Restriction

Prescriber Restriction

Coverage Duration

1 year

Other Criteria

Drugs
ALYFTREK

Covered Uses

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction
Pulmonologist

Coverage Duration
End of Benefit Year

Other Criteria

ANTIFUNGAL

Drugs

Itraconazole Oral, Voriconazole Oral

Covered Uses

Must be used for an FDA Approved Indication

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

Plan Year

Other Criteria

APTIOM

Drugs
APTIOM

Covered Uses
Must be used for an FDA Approved Indication

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration
Plan Year

Other Criteria

Drugs
AQNEURSA

Covered Uses

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration
End of benefit year

Other Criteria

Drugs
ATTRUBY

Covered Uses

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration
End of benefit year

Other Criteria

Drugs

ENBREL MINI, ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5ML, ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE, ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR, HUMIRA (1 PEN), HUMIRA (2 PEN) SUBCUTANEOUS AUTO-INJECTOR KIT 40 MG/0.4ML, HUMIRA (2 SYRINGE) SUBCUTANEOUS PREFILLED SYRINGE KIT 10 MG/0.1ML, 20 MG/0.2ML, 40 MG/0.4ML, HUMIRA-CD/UC/HS STARTER SUBCUTANEOUS AUTO-INJECTOR KIT 80 MG/0.8ML, HUMIRA-PSORIASIS/UVEIT STARTER SUBCUTANEOUS AUTO-INJECTOR KIT, KEVZARA, OLUMIANT, OTEZLA ORAL TABLET 30 MG, OTEZLA ORAL TABLET THERAPY PACK 10 & 20 & 30 MG, RINVOQ, SKYRIZI INTRAVENOUS, SKYRIZI PEN, SKYRIZI SUBCUTANEOUS SOLUTION CARTRIDGE, SKYRIZI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE, STELARA INTRAVENOUS, STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5ML, STELARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 45 MG/0.5ML, 90 MG/ML, TALTZ SUBCUTANEOUS SOLUTION AUTO-INJECTOR, TALTZ SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 20 MG/0.25ML, 40 MG/0.5ML, 80 MG/ML, TREMFYA CROHNS INDUCTION SUBCUTANEOUS SOLUTION AUTO-INJECTOR 200 MG/2ML, TREMFYA INTRAVENOUS, TREMFYA ONE-PRESS, TREMFYA PEN SUBCUTANEOUS SOLUTION AUTO-INJECTOR 100 MG/ML, 200 MG/2ML, TREMFYA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/ML, 200 MG/2ML, XELJANZ ORAL SOLUTION, XELJANZ ORAL TABLET, XELJANZ XR

Covered Uses

Please reference the Select Autoimmune Drugs criteria document posted on hf.org

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Drugs

AVONEX PEN INTRAMUSCULAR AUTO-INJECTOR KIT, AVONEX PREFILLED INTRAMUSCULAR PREFILLED SYRINGE KIT

Covered Uses

All medically accepted indications not otherwise excluded from Part D.

Exclusion Criteria

Treatment of primary progressive MS is not covered. Combination therapy with a beta interferon product, Gilenya, Aubagio, Tecfidera, Tysabri or Copaxone is not covered.

Required Medical Information

Diagnosis of relapsing forms of multiples sclerosis

Age Restriction

Prescriber Restriction

Coverage Duration

1 year

Other Criteria

BRIVIACT

Drugs
BRIVIACT

Covered Uses
Must be used for an FDA Approved Indication

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration
Plan Year

Other Criteria

Drugs

AIMOVIG SUBCUTANEOUS SOLUTION AUTO-INJECTOR 140 MG/ML, 70 MG/ML, AJOVY, EMGALITY, EMGALITY (300 MG DOSE)

Covered Uses

All FDA-approved indications not otherwise excluded from Part D.

Exclusion Criteria

Required Medical Information

Prescriber attestation of migraines and member has tried and failed two formulary alternatives for migraine prophylaxis with two different mechanism of action.

Age Restriction

Prescriber Restriction

Coverage Duration

Through end of benefit year

Other Criteria

CAMPRAL

Drugs

Acamprosate Calcium

Covered Uses

Must be used for an FDA Approved Indication

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

Plan Year

Other Criteria

capecitabine (XELODA)

Drugs

Capecitabine Oral Tablet 150 MG, 500 MG

Covered Uses

All FDA-approved indications not otherwise excluded by Health Plan.

Exclusion Criteria

Required Medical Information

Clinical documentation of FDA approved indication for treatment.

Age Restriction

18 years and older.

Prescriber Restriction

Oncologist

Coverage Duration

Plan year

Other Criteria

CHORIONIC GONADOTROPIN

Drugs

Chorionic Gonadotropin Intramuscular

Covered Uses

Must be used for an FDA Approved Indication

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

Plan Year

Other Criteria

Drugs

COBENFY, COBENFY STARTER PACK

Covered Uses

All FDA-approved indications not otherwise excluded from Part D.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

1 year

Other Criteria

Drugs

COSENTYX (300 MG DOSE), COSENTYX INTRAVENOUS, COSENTYX SENSOREADY (300 MG), COSENTYX SENSOREADY PEN SUBCUTANEOUS SOLUTION AUTO-INJECTOR 150 MG/ML, COSENTYX SUBCUTANEOUS, COSENTYX UNOREADY

Covered Uses

All FDA-approved indications not otherwise excluded from Part D.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Drugs
CRENESSITY ORAL CAPSULE 100 MG, 50 MG, CRENESSITY ORAL SOLUTION

Covered Uses

Exclusion Criteria

Required Medical Information
Must be prescribed for an FDA approved indication.

Age Restriction

Prescriber Restriction

Coverage Duration
End of Benefit Year

Other Criteria

Drugs

ABRYSVO, Adefovir Dipivoxil, **AREXVY**, Armodafinil, Asenapine Maleate, Azelaic Acid External, **BELSOMRA**, Budesonide Oral, Cromolyn Sodium Oral, **EMVERM**, Entecavir Oral Tablet 0.5 MG, 1 MG, **EPCLUSA**, **EUCRISA**, Exemestane, Febuxostat, **FETZIMA**, **FETZIMA TITRATION**, **HYDROcodone Bitartrate ER Oral Tablet ER 24 Hour Abuse-Deterrent 100 MG, 120 MG**, Ivermectin External Lotion, Lacosamide Intravenous, Lacosamide Oral Tablet, lamoTRlgine Oral Tablet Dispersible, Mesalamine Oral Tablet Delayed Release 800 MG, Modafinil Oral, Olopatadine HCl Ophthalmic, Omega-3-acid Ethyl Esters, Phenoxybenzamine HCl Oral, Potassium Chloride Oral Solution 20 MEQ/15ML (10%), 40 MEQ/15ML (20%), **REXULTI**, **SANCUSO**, **SAVELLA**, **SAVELLA TITRATION PACK**, **SIRTURO ORAL TABLET 100 MG**, Tobramycin Inhalation Nebulization Solution 300 MG/4ML, **VEMLIDY**, **VIMPAT INTRAVENOUS**, **VIMPAT ORAL SOLUTION**

Covered Uses

Must be used for an FDA Approved Indication

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

Plan Year

Other Criteria

Drugs
EPIDIOLEX

Covered Uses
Must be used for an FDA Approved Indication

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration
Plan Year

Other Criteria

CYSTADANE

Drugs
Betaine

Covered Uses
Must be used for an FDA Approved Indication

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration
Plan Year

Other Criteria

Drugs
DALIRESP

Covered Uses
Must be used for an FDA Approved Indication

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration
Plan Year

Other Criteria

Drugs
DANZITEN

Covered Uses

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration
End of benefit year

Other Criteria

Drugs

Pyrimethamine Oral

Covered Uses

Must be used for an FDA Approved Indication

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

Plan Year

Other Criteria

Drugs
DIFICID

Covered Uses
Must be used for an FDA Approved Indication

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration
Plan Year

Other Criteria

DIPENTUM

Drugs
DIPENTUM

Covered Uses
Must be used for an FDA Approved Indication

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration
Plan Year

Other Criteria

Drugs

DUPIXENT SUBCUTANEOUS SOLUTION AUTO-INJECTOR 200 MG/1.14ML, 300 MG/2ML, DUPIXENT SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 200 MG/1.14ML, 300 MG/2ML

Covered Uses

All FDA-approved indications not otherwise excluded from Part D.

Exclusion Criteria

Required Medical Information

Patient must have the following: A) Moderate-to-severe atopic dermatitis (eczema) AND submission of medical records (e.g. chart notes, laboratory values) documenting the following: Inadequate response, intolerance or contraindication to ONE medication in EACH of the following categories: a. Topical calcineurin inhibitor b. High potency topical corticosteroid. OR B) Moderate-to-severe asthma AND submission of medical records documenting the following: 1. Patient has ONE of the following: a. Asthma with eosinophilic phenotype with eosinophil count greater than or equal to 300 cells/mcL in the past 12 months, or b. Oral corticosteroid dependent asthma with at least 1 month of daily oral corticosteroid use within the last 3 months AND 2. Inadequate control of asthma symptoms after a minimum of 3 months of compliant use of one of the following: a. Inhaled corticosteroids & long acting beta2 agonist, or b. Inhaled corticosteroids & long acting muscarinic antagonist. OR C) Chronic rhinosinusitis with nasal polyposis (CRSwNP) AND submission of medical records (e.g. chart notes, laboratory values) documenting the following: Inadequate response, intolerance or contraindication to ONE medication in EACH of the following categories: 1. Inadequate response, intolerance or contraindication to ONE medication in EACH of the following categories: a. Nasal corticosteroid spray and b. Oral corticosteroid.

Age Restriction

Prescriber Restriction

Dermatologist or allergist/immunologist

Coverage Duration

Initial Authorization will be for 3 months. Reauthorization will be for 1 year.

Other Criteria

Renewals require submission of medical records (e.g. chart notes, laboratory values) documenting improvement of the condition.

Drugs
EMSAM

Covered Uses
Must be used for an FDA Approved Indication

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration
Plan Year

Other Criteria

EXELON

Drugs

Rivastigmine, Rivastigmine Tartrate

Covered Uses

Must be used for an FDA Approved Indication

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

Plan Year

Other Criteria

FDA Approved Indication

Drugs

AGAMREE, AUGTYRO ORAL CAPSULE 40 MG, BEYFORTUS, FABHALTA, FILSUVEZ, FRUZAQLA, IWILFIN, OGSIVEO, OJJAARA, OMVOH INTRAVENOUS, OMVOH SUBCUTANEOUS SOLUTION AUTO-INJECTOR, REZDIFFRA, RIVFLOZA, SYNAGIS, TASIGNA, *Teriparatide Subcutaneous Solution Pen-Injector 560 MCG/2.24ML*, TRUQAP ORAL TABLET 200 MG, VELSIPITY, WAINUA

Covered Uses

All FDA-approved indications not otherwise excluded from Part D.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Gemtesa

Drugs
GEMTESA

Covered Uses
All FDA-approved indications not otherwise excluded from Part D.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration
End of Benefit Year

Other Criteria

Drugs

Liraglutide, MOUNJARO SUBCUTANEOUS SOLUTION AUTO-INJECTOR, OZEMPIC (0.25 OR 0.5 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 2 MG/3ML, OZEMPIC (1 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 4 MG/3ML, OZEMPIC (2 MG/DOSE), RYBELSUS, TRULICITY SUBCUTANEOUS SOLUTION AUTO-INJECTOR

Covered Uses

All FDA-approved indications not otherwise excluded from Part D.

Exclusion Criteria

Medication is not covered for weight loss related indications

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

Through end of benefit year

Other Criteria

Drugs

NORDITROPIN FLEXPPO SUBCUTANEOUS SOLUTION PEN-INJECTOR, OMNITROPE SUBCUTANEOUS SOLUTION CARTRIDGE, OMNITROPE SUBCUTANEOUS SOLUTION RECONSTITUTED

Covered Uses

All FDA approved indications not otherwise excluded by Health Plan. Additional off-label coverage is provided for (note - some growth hormone drugs may be labeled for 1 or more of these indications): adult growth hormone deficiency, growth failure in children small for gestational age or with intrauterine growth retardation, idiopathic short stature, GH deficiency associated with Turner Syndrome, growth failure secondary to chronic renal failure/insufficiency in children who have not received a renal transplant, short stature associated with Noonan Syndrome, short bowel syndrome, and for the treatment of Prader-Willi Syndrome.

Exclusion Criteria

Coverage is not provided for constitutional delayed growth

Required Medical Information

Pediatric GHD: epiphyses must be confirmed open in patients 10 years of age and older, AND 1. diagnosis confirmed by any 2 provocative tests or by both low IGF-1 and IGFBP-3 levels in patients who meet the height related conditions of coverage, 2. diagnosis confirmed by 2 provocative tests and both low IGF-1 and IGF-BP3 in patients not meeting height related coverage conditions, or 3. 3 pituitary hormone deficiencies in pt with irreversible hypothalamic-pituitary structural lesions or panhypopituitarism. Growth failure from CRF: PGHD criteria must be met without the provocative tests or IGF-1 and IGF-BP3 related conditions. Idiopathic Short Stature: epiphyses must be confirmed as open in patients greater than or equal 10 years of age, height must be less than or equal - 2.25 sds from the mean. Small for Gestational Age: failure to manifest catch up growth by age 2 defined as birth weight, birth length, or both that are more than 2 sds mean normal values following adjustment for age and gender. Turner's syndrome and Noonan Syndrome: epiphyses must be confirmed as open and when on therapy. Adult GHD: requires either 1. a negative GH provocative test when the AGHD is due to childhood onset GHD, pituitary or hypothalamic disease, surgery or radiation therapy, or trauma, OR 2. 3 pituitary hormone deficiencies and baseline serum IGF-I levels below the age- and sex-appropriate reference range when the AGHD is due to irreversible hypothalamic-pituitary structural lesions or panhypopituitarism not acquired as a child, OR 3. 3 pituitary hormone deficiencies if adult panhypopit or irreversible hypothalamic-pituitary structural lesions are from childhood. Short bowel syndrome: when receiving specialized nutritional support.

Age Restriction

7 years of age or older for Idiopathic short stature

Prescriber Restriction

Pediatric endocrinologist for ISS

Coverage Duration

1 month for short bowel syndrome, 12 months for other indications

Other Criteria

Height related conditions of coverage: 1. height below the third percentile for their age and gender related height, 2. growth velocity subnormal greater than or equal 2 standard deviations (sds) from the age related mean, 3. delayed skeletal maturation greater than or equal 2 sds below the age/gender related mean. Renewals for PGHD, CFR, SGA, Turner's and Noonan Syndromes require growth response of greater than or equal 4.5 cm/yr (pre-pubertal) or greater than or equal 2.5 cm/yr (post-pubertal) AND open epiphyses. For pediatric patients with irreversible hypothalamic-pituitary structural lesions or panhypopituitarism coverage is renewable if the patient has had 3 pituitary hormone deficiencies. Renewals for short bowel syndrome is provided in the presence of clinical benefit (such as, decreasing the patient's intravenous nutritional requirements). Renewals for Prader-Willi syndrome is provided if pt has increase in lean body mass or decrease in fat mass. Renewals for ISS is provided in the presence of a growth response of greater than or equal 1.5 cm/yr AND open epiphyses. Renewals for AGHD is provided in the presence of clinical benefit (e.g., increase in total lean body mass, increase in IGF-1 and IGFBP-3 levels, or increase in exercise capacity).

Drugs
HYMPAVZI

Covered Uses
All FDA-approved indications not otherwise excluded from Part D.

Exclusion Criteria

Required Medical Information
Diagnosis of Hemophilia A or Hemophilia B

Age Restriction

Prescriber Restriction

Coverage Duration
12 months

Other Criteria

IMBRUVICA (Ibrutinib)

Drugs
IMBRUVICA ORAL SUSPENSION

Covered Uses
All FDA-approved indications not otherwise excluded from Health Plan.

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration
3 Months

Other Criteria

Imkeldi (imatinib)

Drugs
Imkeldi

Covered Uses

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration
End of benefit year

Other Criteria

ISOTRETINOIN

Drugs

ISotretinoin Oral Capsule 10 MG, 20 MG, 30 MG, 40 MG

Covered Uses

Must be used for an FDA Approved Indication

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

Plan Year

Other Criteria

Drugs
ITOVEBI

Covered Uses

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction
Oncologist

Coverage Duration
End of Benefit Year

Other Criteria

LIDODERM

Drugs

Lidocaine External Patch 5 %

Covered Uses

Must be used for an FDA Approved Indication

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

Plan Year

Other Criteria

Drugs
LIVDELZI

Covered Uses

Exclusion Criteria

Required Medical Information

Documentation that the patients ALP was greater than or equal to 1.67-times the ULN AND total bilirubin (TB) was less than or equal to 2-times the ULN. AND Patient does not have a history of a hepatic decompensation event including portal hypertension with complications, or cirrhosis with complications (e.g., Model for End Stage Liver Disease [MELD] score of 12 or greater, known esophageal varices or history of variceal bleeds, history of hepatorenal syndrome).

Age Restriction

Prescriber Restriction

Coverage Duration

Plan Year

Other Criteria

Drugs

Alosetron HCl

Covered Uses

Must be used for an FDA Approved Indication

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

Plan Year

Other Criteria

Drugs

BELBUCA BUCCAL FILM 600 MCG, 750 MCG, 900 MCG, *fentaNYL Transdermal Patch 72 Hour 100 MCG/HR, 50 MCG/HR, 75 MCG/HR, HYDROmorphone HCl ER Oral Tablet Extended Release 24 Hour 32 MG, Morphine Sulfate ER Beads Oral Capsule Extended Release 24 Hour 120 MG, Morphine Sulfate ER Oral Capsule Extended Release 24 Hour 100 MG, Morphine Sulfate ER Oral Tablet Extended Release 100 MG, 200 MG, 60 MG, oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 20 MG, 30 MG, OxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 40 MG, traMADol HCl ER Oral Tablet Extended Release 24 Hour 200 MG, 300 MG*

Covered Uses

Must be used for an FDA Approved Indication

Exclusion Criteria**Required Medical Information****Age Restriction****Prescriber Restriction****Coverage Duration**

Plan Year

Other Criteria

Drugs

ALVESCO INHALATION AEROSOL SOLUTION 160 MCG/ACT, 80 MCG/ACT, PLEGRIDY INTRAMUSCULAR, PLEGRIDY STARTER PACK SUBCUTANEOUS SOLUTION AUTO-INJECTOR, PLEGRIDY STARTER PACK SUBCUTANEOUS SOLUTION PREFILLED SYRINGE, PLEGRIDY SUBCUTANEOUS SOLUTION AUTO-INJECTOR, PLEGRIDY SUBCUTANEOUS SOLUTION PREFILLED SYRINGE, SOVALDI, ZEPATIER

Covered Uses

Must be used for an FDA Approved Indication

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

Plan Year

Other Criteria

MULTAQ

Drugs
MULTAQ

Covered Uses
Must be used for an FDA Approved Indication

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration
Plan Year

Other Criteria

Drugs
NUEDEXTA

Covered Uses
Must be used for an FDA Approved Indication

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration
Plan Year

Other Criteria

Drugs
NURTEC

Covered Uses

All FDA-approved indications not otherwise excluded from Part D.

Exclusion Criteria

Required Medical Information

Documentation that the medication will be used for the acute treatment of migraine with or without aura in adults AND member has tried and failed two triptan therapies OR Documentation that the medication will be used for the prevention of migraine with or without aura in adults AND member has tried and failed two preventative medication alternatives

Age Restriction

Prescriber Restriction

Coverage Duration

Through end of benefit year

Other Criteria

Reauthorization requires documentation of medication efficacy.

Drugs

OMNIPOD 5 DEXG7G6 INTRO GEN 5, OMNIPOD 5 DEXG7G6 PODS GEN 5, OMNIPOD 5 LIBRE2 G6 INTRO G5, OMNIPOD 5 LIBRE2 PLUS G6 PODS, OMNIPOD DASH INTRO (GEN 4), OMNIPOD DASH PDM (GEN 4), OMNIPOD DASH PODS (GEN 4), OMNIPOD POD PALS

Covered Uses

All FDA-approved indications not otherwise excluded from Part D.

Exclusion Criteria**Required Medical Information**

Initial therapy: 1) Member has a diagnosis of Type 1 Diabetes OR 2) Member has a diagnosis of Type 2 Diabetes AND A) Member takes 3 or more insulin injections a day (OR is currently on an insulin pump) AND B) Member checks blood glucose 3 or more times a day (OR is currently on a CGM device).

Age Restriction

None

Prescriber Restriction

Endocrinologist

Coverage Duration

12 months

Other Criteria

If request is for more than 10 pods per 30 days additional documentation is required to provide clinical rationale for higher quantity

Drugs

cloBAZam Oral Suspension 2.5 MG/ML, cloBAZam Oral Tablet

Covered Uses

Must be used for an FDA Approved Indication

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

Plan Year

Other Criteria

PANCRELIPASE

Drugs
CREON, VIOKACE, ZENPEP ORAL CAPSULE DELAYED RELEASE PARTICLES 10000-32000 UNIT, 15000-47000 UNIT, 20000-63000 UNIT, 25000-79000 UNIT, 3000-10000 UNIT, 40000-126000 UNIT, 5000-24000 UNIT

Covered Uses
Must be used for an FDA Approved Indication

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration
Plan Year

Other Criteria

RETINOIDS

Drugs

*Adapalene External Cream, Adapalene External Gel, Tazarotene External Cream 0.1 %, **TAZORAC EXTERNAL CREAM 0.05 %**, **TAZORAC EXTERNAL GEL**, Tretinoin External, Tretinoin Microsphere External Gel 0.1 %, Tretinoin Microsphere Pump External Gel 0.04 %*

Covered Uses

Must be used for an FDA Approved Indication

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

Plan Year

Other Criteria

REVLIMID (Lenalidomide)

Drugs

REVLIMID ORAL CAPSULE 10 MG, 15 MG, 2.5 MG, 20 MG, 25 MG, 5 MG

Covered Uses

All FDA-approved indications not otherwise excluded by Health Plan.

Exclusion Criteria

Pregnancy (category X)

Required Medical Information

Diagnosis of one of the following: A) Multiple myeloma used in combination with dexamethasone, or B) Diagnosis of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities, or C) Mantle cell lymphoma and patient's disease has relapsed or progressed after trying at least two prior therapies (Velcade and one of the following: bendamustine, cladribine, fludarabine, rituximab) AND patient is enrolled in the Revlimid REMS Program.

Age Restriction

18 years and older

Prescriber Restriction

Hematologist/oncologist. Registered in Revlimid REMS.

Coverage Duration

3 Months

Other Criteria

Drugs
REVUFORJ

Covered Uses

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration
End of benefit year

Other Criteria

Drugs
ROZLYTREK

Covered Uses

All FDA-approved indications not otherwise excluded from Part D.

Exclusion Criteria

Required Medical Information

Documentation of: A) metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive OR B) solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation AND are metastatic or where surgical resection is likely to result in severe morbidity AND have either progressed following treatment or have no satisfactory alternative therapy.

Age Restriction

12 years of age or older

Prescriber Restriction

Oncology

Coverage Duration

3 months

Other Criteria

Drugs

Abiraterone Acetate Oral Tablet 250 MG, 500 MG, **ACTEMRA ACTPEN, ACTEMRA SUBCUTANEOUS, ACTIMMUNE, ADEMPAS, ALECENSA, Ambrisentan, APOKYN SUBCUTANEOUS SOLUTION CARTRIDGE, ARANESP (ALBUMIN FREE) INJECTION SOLUTION 100 MCG/ML, 200 MCG/ML, 25 MCG/ML, 40 MCG/ML, 60 MCG/ML, ARANESP (ALBUMIN FREE) INJECTION SOLUTION PREFILLED SYRINGE, ARCALYST, azaCITIDine, BETASERON SUBCUTANEOUS KIT, Bexarotene, Bosentan Oral Tablet, BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MG, CAPRELSA ORAL TABLET 100 MG, 300 MG, Carglumic Acid Oral Tablet Soluble, CAYSTON, CERDELGA, Cinacalcet HCl Oral Tablet 30 MG, 60 MG, 90 MG, CINRYZE, COMETRIQ (100 MG DAILY DOSE) ORAL KIT 80 & 20 MG, COMETRIQ (140 MG DAILY DOSE) ORAL KIT 3 X 20 MG & 80 MG, COMETRIQ (60 MG DAILY DOSE), COPAXONE SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 20 MG/ML, 40 MG/ML, COTELLIC, CYSTAGON, CYSTARAN, Dalfampridine ER, Decitabine, Deferiprone, Dimethyl Fumarate Oral Capsule Delayed Release 120 MG, 240 MG, Dimethyl Fumarate Starter Pack Oral Capsule Delayed Release Therapy Pack, ELIGARD, Eltrombopag Olamine Oral Tablet 12.5 MG, 25 MG, 50 MG, 75 MG, EPCUSA, Epoprostenol Sodium, ERBITUX, ERIVEDGE, ERLEADA ORAL TABLET 60 MG, Erlotinib HCl Oral Tablet 100 MG, 150 MG, 25 MG, ESBRIET ORAL CAPSULE, ESBRIET ORAL TABLET 267 MG, 801 MG, Everolimus Oral Tablet 2.5 MG, 5 MG, 7.5 MG, FERRIPROX ORAL SOLUTION, FERRIPROX TWICE-A-DAY, Fingolimod HCl, GAZYVA, HARVONI, HEMLIBRA SUBCUTANEOUS SOLUTION 105 MG/0.7ML, 150 MG/ML, 30 MG/ML, 60 MG/0.4ML, HETLIOZ, HYQVIA, IBRANCE, Icatibant Acetate Subcutaneous Solution Prefilled Syringe, ICLUSIG, IDHIFA, Imatinib Mesylate Oral Tablet 100 MG, 400 MG, IMBRUVICA ORAL CAPSULE 140 MG, 70 MG, IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG, INCRELEX, INLYTA ORAL TABLET 1 MG, 5 MG, JAKAFI, KADCYLA, KALYDECO ORAL PACKET 25 MG, 50 MG, 75 MG, KALYDECO ORAL TABLET, KESIMPTA, KEYTRUDA INTRAVENOUS SOLUTION, KISQALI (200 MG DOSE), KISQALI (400 MG DOSE), KISQALI (600 MG DOSE), Lapatinib Ditosylate, LENVIMA (10 MG DAILY DOSE), LENVIMA (12 MG DAILY DOSE), LENVIMA (14 MG DAILY DOSE), LENVIMA (18 MG DAILY DOSE), LENVIMA (20 MG DAILY DOSE), LENVIMA (24 MG DAILY DOSE), LENVIMA (4 MG DAILY DOSE), LENVIMA (8 MG DAILY DOSE), Leuprolide Acetate Injection, LORBRENA ORAL TABLET 100 MG, 25 MG, LUPRON DEPOT-PED (1-MONTH), LUPRON DEPOT-PED (3-MONTH), LYNPARZA ORAL TABLET, MAYZENT ORAL TABLET 0.25 MG, 1 MG, 2 MG, MEKINIST ORAL TABLET 0.5 MG, 2 MG, MIRCERA INJECTION SOLUTION PREFILLED SYRINGE 100 MCG/0.3ML, 150 MCG/0.3ML, 200 MCG/0.3ML, 30 MCG/0.3ML, 50 MCG/0.3ML, 75 MCG/0.3ML, mitoXANTRONE HCl, MYALEPT, NEXAVAR, Nitisinone Oral Capsule 10 MG, 2 MG, 5 MG, NIVESTYM, NUCALA SUBCUTANEOUS SOLUTION AUTO-INJECTOR, NUCALA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/ML, NUCALA SUBCUTANEOUS SOLUTION RECONSTITUTED, Octreotide Acetate Injection Solution 100 MCG/ML, 1000 MCG/ML, 200 MCG/ML, 50 MCG/ML, 500 MCG/ML, ODOMZO, ONCASPAR INJECTION, OPSUMIT, ORENITRAM, ORFADIN ORAL CAPSULE 20 MG, ORFADIN ORAL SUSPENSION, ORKAMBI ORAL PACKET 100-125 MG, 150-188 MG, ORKAMBI ORAL TABLET, PAZOPanib HCl, PEGASYS SUBCUTANEOUS SOLUTION 180 MCG/ML, PEGASYS SUBCUTANEOUS SOLUTION PREFILLED SYRINGE, POMALYST, PRALUENT SUBCUTANEOUS SOLUTION AUTO-INJECTOR, PROLASTIN-C INTRAVENOUS SOLUTION, PROLIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE, PROMACTA ORAL TABLET 12.5 MG, 25 MG, 50 MG, 75 MG, REBIF REBIDOSE SUBCUTANEOUS SOLUTION AUTO-INJECTOR, REBIF REBIDOSE TITRATION PACK SUBCUTANEOUS SOLUTION AUTO-INJECTOR, REBIF SUBCUTANEOUS SOLUTION PREFILLED SYRINGE, REBIF TITRATION PACK SUBCUTANEOUS SOLUTION PREFILLED SYRINGE, REMODULIN INJECTION SOLUTION 100 MG/20ML, 20 MG/20ML, 200 MG/20ML, 50 MG/20ML, RETACRIT INJECTION SOLUTION 10000 UNIT/ML, 2000 UNIT/ML, 20000 UNIT/ML, 3000 UNIT/ML, 4000 UNIT/ML, 40000 UNIT/ML, Ribavirin Oral Capsule, Ribavirin Oral Tablet 200 MG, RYDAPT, Sapropterin Dihydrochloride Oral Packet, Sapropterin Dihydrochloride Oral Tablet, SIGNIFOR, Sildenafil Citrate Intravenous, Sildenafil Citrate Oral Tablet 20 MG, SIMPONI ARIA, SIMPONI SUBCUTANEOUS SOLUTION AUTO-INJECTOR, SIMPONI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE, Sodium Phenylbutyrate Oral Powder 3 GM/TSP, Sodium Phenylbutyrate Oral Tablet, SOMATULINE DEPOT, SOMAVERT, SPRYCEL ORAL TABLET 100 MG, 140 MG, 20 MG, 50 MG, 70 MG, 80 MG, STIVARGA, SUNItinib Malate, SYMDEKO, TAFINLAR ORAL CAPSULE, TARGRETIN EXTERNAL, TEMODAR INTRAVENOUS, Temozolomide, Tetrabenazine Oral Tablet 12.5 MG, 25 MG, THALOMID ORAL CAPSULE 100 MG, 50 MG, Tobramycin Inhalation Nebulization Solution 300 MG/5ML, Tolvaptan Oral Tablet, TRIKAFTA ORAL TABLET THERAPY PACK, TYMLOS, TYSABRI, TYVASO, TYVASO REFILL KIT, TYVASO STARTER KIT, UPTRAVI INTRAVENOUS, UPTRAVI ORAL TABLET 1000 MCG, 1200 MCG, 1400 MCG, 1600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG, UPTRAVI TITRATION, VENCLEXTA ORAL TABLET 10 MG, 100 MG, 50 MG, VENCLEXTA STARTING PACK, VENTAVIS, Vigabatrin, VITRAKVI ORAL CAPSULE 100 MG, 25 MG, VITRAKVI ORAL SOLUTION, VOSEVI, VOTRIENT, VUMERITY, XALKORI ORAL CAPSULE, XOLAIR SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150 MG/ML, 75 MG/0.5ML, XOLAIR SUBCUTANEOUS SOLUTION RECONSTITUTED, XTANDI ORAL CAPSULE, ZELBORAF, Zoledronic Acid Intravenous Concentrate, Zoledronic Acid Intravenous Solution 5 MG/100ML, ZOLINZA, ZYDELIG, ZYKADIA ORAL TABLET**

Covered Uses

Must be used for an FDA Approved Indication

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

Plan Year

Other Criteria

SUCRAID

Drugs
SUCRAID

Covered Uses
Must be used for an FDA Approved Indication

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration
Plan Year

Other Criteria

Drugs
SYNAREL

Covered Uses
Must be used for an FDA Approved Indication

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration
Plan Year

Other Criteria

Tadalafil

Drugs

Tadalafil (PAH), Tadalafil Oral Tablet 2.5 MG, 5 MG

Covered Uses

All FDA-approved indications not otherwise excluded from Part D.

Exclusion Criteria

Medication used for Erectile Dysfunction are excluded from coverage.

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

Plan Year

Other Criteria

TESTOSTERONE

Drugs

methy/TESTOSTERone Oral, Testosterone Transdermal Gel 10 MG/ACT (2%), 25 MG/2.5GM (1%)

Covered Uses

Must be used for an FDA Approved Indication

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

Plan Year

Other Criteria

TESTOSTERONE REPLACEMENT

Drugs

Testosterone Enanthate Intramuscular Solution

Covered Uses

All FDA-approved indications not otherwise excluded by Health Plan.

Exclusion Criteria

Male patients with normal or above normal testosterone levels (normal equal to 270-1070 ng/dl or 9.3-37 mmol), breast cancer in males, hypersensitivity to testosterone or any component of the product, pregnancy, known or suspected prostate cancer, use of the gel or patch in women

Required Medical Information

Statement indicating diagnosis of hypogonadism in men with pretreatment testosterone level below normal physiological value of 300 ng/dl or below normal reference level provided by the laboratory required.

Age Restriction

18 years or older

Prescriber Restriction

Coverage Duration

Through the benefit year

Other Criteria

Drugs
TRYNGOLZA

Covered Uses

Exclusion Criteria

Required Medical Information

Age Restriction
18 years of age or older

Prescriber Restriction
Endocrinologist

Coverage Duration
End of benefit year

Other Criteria

VIIBRYD (vilazodone)

Drugs

VIIBRYD ORAL TABLET, *Vilazodone HCl*

Covered Uses

All FDA-approved indications not otherwise excluded from Part D.

Exclusion Criteria

Required Medical Information

Documented trial of at least two generic antidepressants (e.g. bupropion, citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, paroxetine CR, sertraline, duloxetine, venlafaxine).

Age Restriction

Prescriber Restriction

Coverage Duration

Through end of benefit year

Other Criteria

Drugs
VIVITROL

Covered Uses

All FDA-approved indications not otherwise excluded from Part D.

Exclusion Criteria

Required Medical Information

Diagnosis of 1 of the following: A) for the treatment of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting prior to initiation of treatment with Vivitrol. Patients should not be actively drinking at the time of initial Vivitrol administration or B) I is indicated for the prevention of relapse to opioid dependence, following opioid detoxification

Age Restriction

18 years of age or older

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Drugs
VOQUEZNA

Covered Uses

Exclusion Criteria

Required Medical Information
Patient must try and fail or have a contraindication to two(2) drugs from the proton pump inhibitor (PPI) class

Age Restriction

Prescriber Restriction

Coverage Duration
End of the Benefit Year

Other Criteria

Drugs
WEGOVY

Covered Uses

All FDA-approved indications not otherwise excluded from Part D.

Exclusion Criteria

Wegovy is not covered for weight loss related indications

Required Medical Information

Documentation that the medication will be used to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight. Established Cardiovascular disease is defined as prior myocardial infarction, prior stroke, or peripheral arterial disease.

Age Restriction

Prescriber Restriction

Must be prescribed by or in consultation with a cardiologist

Coverage Duration

Plan Year

Other Criteria

Drugs

Acyclovir External Ointment, **BARACLUDE ORAL SOLUTION**, **DIFICID**, **KERENDIA ORAL TABLET 10 MG, 20 MG**, *Levorphanol Tartrate Oral*, **NYVEPRIA**, *Oxiconazole Nitrate*, **REMICADE**, **SUNOSI**, **TOVIAZ**, **VERZENIO**, **XTANDI ORAL TABLET 40 MG, 80 MG**, **ZEPOSIA**, **ZEPOSIA 7-DAY STARTER PACK**

Covered Uses

Must be used for an FDA Approved Indication

Exclusion Criteria**Required Medical Information****Age Restriction****Prescriber Restriction****Coverage Duration**

Plan Year

Other Criteria

XIFAXAN

Drugs

XIFAXAN ORAL TABLET 200 MG, 550 MG

Covered Uses

Must be used for an FDA Approved Indication

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

Plan Year

Other Criteria

Drugs

Bexarotene, **EPCLUSA**, **MAYZENT STARTER PACK**, *Pirfenidone Oral Tablet 267 MG, 801 MG*, **RESTASIS**, *SORafenib Tosylate*

Covered Uses

Must be used for an FDA Approved Indication

Exclusion Criteria

Required Medical Information

Age Restriction

Prescriber Restriction

Coverage Duration

Plan Year

Other Criteria

Drugs

ZEPBOUND SUBCUTANEOUS SOLUTION 10 MG/0.5ML, 2.5 MG/0.5ML, 5 MG/0.5ML, 7.5 MG/0.5ML, ZEPBOUND SUBCUTANEOUS SOLUTION AUTO-INJECTOR

Covered Uses

All FDA-approved indications not otherwise excluded from Part D.

Exclusion Criteria

Zepbound is not covered for weight loss related indications. Obesity is an excluded indication.

Required Medical Information

Obstructive Sleep Apnea (OSA): The patient must 1) Have a BMI of 30 or higher AND 2) Have a documented sleep study confirming the diagnosis of OSA AND 3) Documentation showing the patient has failed managing OSA with a CPAP device AND 4) Confirmation of moderate to severe sleep apnea as defined by an Apnea-hypopnea index (AHI) of 15 or greater.

Age Restriction

Prescriber Restriction

Coverage Duration

12 months

Other Criteria

Index

<i>Abiraterone Acetate Oral Tablet</i>		<i>Bexarotene</i>	53, 67	<i>Dimethyl Fumarate Starter Pack</i>	
250 MG, 500 MG.....	53	BEYFORTUS	29	<i>Oral Capsule Delayed Release</i>	
ABRYSVO	18	<i>Bosentan Oral Tablet</i>	53	<i>Therapy Pack</i>	53
<i>Acamprosate Calcium</i>	12	BOSULIF ORAL TABLET 100		DIPENTUM	25
ACTEMRA ACTPEN	53	MG, 400 MG, 500 MG	53	DUPIXENT SUBCUTANEOUS	
ACTEMRA SUBCUTANEOUS	53	BRIVIACT	10	SOLUTION AUTO-INJECTOR 200	
ACTIMMUNE	53	<i>Budesonide Oral</i>	18	MG/1.14ML, 300 MG/2ML	26
<i>Acyclovir External Ointment</i>	65	<i>Capecitabine Oral Tablet 150 MG,</i>		DUPIXENT SUBCUTANEOUS	
<i>Adapalene External Cream</i>	49	<i>500 MG</i>	13	SOLUTION PREFILLED SYRINGE	
<i>Adapalene External Gel</i>	49	CAPRELSA ORAL TABLET 100		200 MG/1.14ML, 300 MG/2ML	26
<i>Adefovir Dipivoxil</i>	18	MG, 300 MG	53	ELIGARD	53
ADEMPAS	53	<i>Carglumic Acid Oral Tablet Soluble</i>	53	<i>Eltrombopag Olamine Oral Tablet</i>	
AGAMREE	29	CAYSTON	53	<i>12.5 MG, 25 MG, 50 MG, 75 MG</i>	53
AIMOVIG SUBCUTANEOUS		CERDELGA	53	EMGALITY	11
SOLUTION AUTO-INJECTOR 140		<i>Chorionic Gonadotropin</i>		EMGALITY (300 MG DOSE)	11
MG/ML, 70 MG/ML	11	<i>Intramuscular</i>	14	EMSAM	27
AJOVY	11	<i>Cinacalcet HCl Oral Tablet 30 MG,</i>		EMVERM	18
ALDURAZYME	1	<i>60 MG, 90 MG</i>	53	ENBREL MINI	8
ALECENSA	53	CINRYZE	53	ENBREL SUBCUTANEOUS	
ALHEMO	2	<i>cloBAZam Oral Suspension 2.5</i>		SOLUTION 25 MG/0.5ML	8
<i>Alosetron HCl</i>	40	<i>MG/ML</i>	47	ENBREL SUBCUTANEOUS	
ALVESCO INHALATION		<i>cloBAZam Oral Tablet</i>	47	SOLUTION PREFILLED SYRINGE ..	8
AEROSOL SOLUTION 160		COBENFY	15	ENBREL SURECLICK	
MCG/ACT, 80 MCG/ACT	42	COBENFY STARTER PACK	15	SUBCUTANEOUS SOLUTION	
ALYFTREK	3	COMETRIQ (100 MG DAILY		AUTO-INJECTOR	8
<i>Ambrisentan</i>	53	DOSE) ORAL KIT 80 & 20 MG	53	<i>Entecavir Oral Tablet 0.5 MG, 1</i>	
APOKYN SUBCUTANEOUS		COMETRIQ (140 MG DAILY		<i>MG</i>	18
SOLUTION CARTRIDGE	53	DOSE) ORAL KIT 3 X 20 MG & 80		EPCLUSA	18, 53, 67
APTIOM	5	MG	53	EPIDIOLEX	19
AQNEURSA	6	COMETRIQ (60 MG DAILY DOSE)	53	<i>Epoprostenol Sodium</i>	53
ARANESP (ALBUMIN FREE)		COPAXONE SUBCUTANEOUS		ERBITUX	53
INJECTION SOLUTION 100		SOLUTION PREFILLED SYRINGE		ERIVEDGE	53
MCG/ML, 200 MCG/ML, 25		20 MG/ML, 40 MG/ML	53	ERLEADA ORAL TABLET 60 MG	53
MCG/ML, 40 MCG/ML, 60		COSENTYX (300 MG DOSE)	16	<i>Erlotinib HCl Oral Tablet 100 MG,</i>	
MCG/ML	53	COSENTYX INTRAVENOUS	16	<i>150 MG, 25 MG</i>	53
ARANESP (ALBUMIN FREE)		COSENTYX SENSOREADY (300		ESBRIET ORAL CAPSULE	53
INJECTION SOLUTION		MG)	16	ESBRIET ORAL TABLET 267 MG,	
PREFILLED SYRINGE	53	COSENTYX SENSOREADY PEN		801 MG	53
ARCALYST	53	SUBCUTANEOUS SOLUTION		EUCRISA	18
AREXVY	18	AUTO-INJECTOR 150 MG/ML	16	<i>Everolimus Oral Tablet 2.5 MG, 5</i>	
<i>Armodafinil</i>	18	COSENTYX SUBCUTANEOUS	16	<i>MG, 7.5 MG</i>	53
<i>Asenapine Maleate</i>	18	COSENTYX UNOREADY	16	<i>Exemestane</i>	18
ATTRUBY	7	COTELLIC	53	FABHALTA	29
AUGTYRO ORAL CAPSULE 40		CRENESSITY ORAL CAPSULE		<i>Febuxostat</i>	18
MG	29	100 MG, 50 MG	17	<i>fentaNYL Transdermal Patch 72</i>	
AVONEX PEN INTRAMUSCULAR		CRENESSITY ORAL SOLUTION ..	17	<i>Hour 100 MCG/HR, 50 MCG/HR,</i>	
AUTO-INJECTOR KIT	9	CREON	48	<i>75 MCG/HR</i>	41
AVONEX PREFILLED		<i>Cromolyn Sodium Oral</i>	18	FERRIPROX ORAL SOLUTION	53
INTRAMUSCULAR PREFILLED		CYSTAGON	53	FERRIPROX TWICE-A-DAY	53
SYRINGE KIT	9	CYSTARAN	53	FETZIMA	18
<i>azaCITIDine</i>	53	<i>Dalfampridine ER</i>	53	FETZIMA TITRATION	18
<i>Azelaic Acid External</i>	18	DALIRESP	21	FILSUVEZ	29
BARACLUDE ORAL SOLUTION ...	65	DANZITEN	22	<i>Fingolimod HCl</i>	53
BELBUCA BUCCAL FILM 600		<i>Decitabine</i>	53	FRUZAQLA	29
MCG, 750 MCG, 900 MCG	41	<i>Deferiprone</i>	53	GAZYVA	53
BELSOMRA	18	DIFICID	24, 65	GEMTESA	30
<i>Betaine</i>	20	<i>Dimethyl Fumarate Oral Capsule</i>		HARVONI	53
BETASERON SUBCUTANEOUS		<i>Delayed Release 120 MG, 240 MG</i>	53		
KIT	53				

HEMLIBRA SUBCUTANEOUS SOLUTION 105 MG/0.7ML, 150 MG/ML, 30 MG/ML, 60 MG/0.4ML	53	KISQALI (400 MG DOSE)	53	NORDITROPIN FLEXP	
HETLIOZ	53	KISQALI (600 MG DOSE)	53	SUBCUTANEOUS SOLUTION	
HUMIRA (1 PEN)	8	<i>Lacosamide Intravenous</i>	18	PEN-INJECTOR	32
HUMIRA (2 PEN)		<i>Lacosamide Oral Tablet</i>	18	NUCALA SUBCUTANEOUS SOLUTION AUTO-INJECTOR	53
SUBCUTANEOUS AUTO-INJECTOR KIT 40 MG/0.4ML	8	<i>lamoTRlgine Oral Tablet Dispersible</i>	18	NUCALA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/ML	53
HUMIRA (2 SYRINGE) SUBCUTANEOUS PREFILLED SYRINGE KIT 10 MG/0.1ML, 20 MG/0.2ML, 40 MG/0.4ML	8	<i>Lapatinib Ditosylate</i>	53	NUCALA SUBCUTANEOUS SOLUTION RECONSTITUTED	53
HUMIRA-CD/UC/HS STARTER SUBCUTANEOUS AUTO-INJECTOR KIT 80 MG/0.8ML	8	LENVIMA (10 MG DAILY DOSE)	53	NUDEXTA	44
HUMIRA-PSORIASIS/UEIT STARTER SUBCUTANEOUS AUTO-INJECTOR KIT	8	LENVIMA (12 MG DAILY DOSE)	53	NURTEC	45
<i>HYDROcodone Bitartrate ER Oral Tablet ER 24 Hour Abuse-Deterrent 100 MG, 120 MG</i>	18	LENVIMA (14 MG DAILY DOSE)	53	NYVEPRIA	65
<i>HYDROmorphone HCl ER Oral Tablet Extended Release 24 Hour 32 MG</i>	41	LENVIMA (18 MG DAILY DOSE)	53	<i>Octreotide Acetate Injection Solution 100 MCG/ML, 1000 MCG/ML, 200 MCG/ML, 50 MCG/ML, 500 MCG/ML</i>	53
HYMPAVZI	33	LENVIMA (20 MG DAILY DOSE)	53	ODOMZO	53
HYQVIA	53	LENVIMA (24 MG DAILY DOSE)	53	OGSIVEO	29
IBRANCE	53	LENVIMA (4 MG DAILY DOSE)	53	OJJAARA	29
<i>Icatibant Acetate Subcutaneous Solution Prefilled Syringe</i>	53	LENVIMA (8 MG DAILY DOSE)	53	<i>Olopatadine HCl Ophthalmic</i>	18
ICLUSIG	53	<i>Leuprolide Acetate Injection</i>	53	OLUMIANT	8
IDHIFA	53	<i>Levorphanol Tartrate Oral</i>	65	<i>Omega-3-acid Ethyl Esters</i>	18
<i>Imatinib Mesylate Oral Tablet 100 MG, 400 MG</i>	53	<i>Lidocaine External Patch 5 %</i>	38	OMNIPOD 5 DEXG7G6 INTRO GEN 5	46
IMBRUVICA ORAL CAPSULE 140 MG, 70 MG	53	<i>Liraglutide</i>	31	OMNIPOD 5 DEXG7G6 PODS GEN 5	46
IMBRUVICA ORAL SUSPENSION	34	LIVDELZI	39	OMNIPOD 5 DEXG7G6 PODS GEN 5	46
IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG	53	LORBRENA ORAL TABLET 100 MG, 25 MG	53	OMNIPOD 5 LIBRE2 G6 INTRO G5	46
<i>Imkeldi</i>	35	LUPRON DEPOT-PED (1-MONTH)	53	OMNIPOD 5 LIBRE2 PLUS G6 PODS	46
INCRELEX	53	LUPRON DEPOT-PED (3-MONTH)	53	OMNIPOD DASH INTRO (GEN 4)	46
INLYTA ORAL TABLET 1 MG, 5 MG	53	LYNPARZA ORAL TABLET	53	OMNIPOD DASH PDM (GEN 4)	46
<i>ISotretinoin Oral Capsule 10 MG, 20 MG, 30 MG, 40 MG</i>	36	MAYZENT ORAL TABLET 0.25 MG, 1 MG, 2 MG	53	OMNIPOD DASH PODS (GEN 4)	46
ITOVEBI	37	MAYZENT STARTER PACK	67	OMNIPOD POD PALS	46
<i>Itraconazole Oral</i>	4	MEKINIST ORAL TABLET 0.5 MG, 2 MG	53	OMNITROPE SUBCUTANEOUS SOLUTION CARTRIDGE	32
<i>Ivermectin External Lotion</i>	18	<i>Mesalamine Oral Tablet Delayed Release 800 MG</i>	18	OMNITROPE SUBCUTANEOUS SOLUTION RECONSTITUTED	32
IWILFIN	29	<i>methylTESTOSTERone Oral</i>	58	OMVOH INTRAVENOUS	29
JAKAFI	53	MIRCERA INJECTION SOLUTION PREFILLED SYRINGE 100 MCG/0.3ML, 150 MCG/0.3ML, 200 MCG/0.3ML, 30 MCG/0.3ML, 50 MCG/0.3ML, 75 MCG/0.3ML	53	OMVOH SUBCUTANEOUS SOLUTION AUTO-INJECTOR	29
KADCYLA	53	<i>mitoXANTRONE HCl</i>	53	ONCASPAR INJECTION	53
KALYDECO ORAL PACKET 25 MG, 50 MG, 75 MG	53	<i>Modafinil Oral</i>	18	OPSUMIT	53
KALYDECO ORAL TABLET	53	<i>Morphine Sulfate ER Beads Oral Capsule Extended Release 24 Hour 120 MG</i>	41	ORENITRAM	53
KERENDIA ORAL TABLET 10 MG, 20 MG	65	<i>Morphine Sulfate ER Oral Capsule Extended Release 24 Hour 100 MG</i>	41	ORFADIN ORAL CAPSULE 20 MG	53
KESIMPTA	53	<i>Morphine Sulfate ER Oral Tablet Extended Release 100 MG, 200 MG, 60 MG</i>	41	ORFADIN ORAL SUSPENSION	53
KEVZARA	8	MOUNJARO SUBCUTANEOUS SOLUTION AUTO-INJECTOR	31	ORKAMBI ORAL PACKET 100-125 MG, 150-188 MG	53
KEYTRUDA INTRAVENOUS SOLUTION	53	MULTAQ	43	ORKAMBI ORAL TABLET	53
KISQALI (200 MG DOSE)	53	MYALEPT	53	OTEZLA ORAL TABLET 30 MG	8
		<i>Nitisinone Oral Capsule 10 MG, 2 MG, 5 MG</i>	53	OTEZLA ORAL TABLET THERAPY PACK 10 & 20 & 30 MG	8
		NIVESTYM	53	<i>Oxiconazole Nitrate</i>	65
				<i>oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 20 MG, 30 MG</i>	41

<i>OxyMORphone HCl ER Oral Tablet</i>		RETACRIT INJECTION		<i>SUNItinib Malate</i>	53
<i>Extended Release 12 Hour 40 MG..</i>	41	SOLUTION 10000 UNIT/ML, 2000		SUNOSI	65
OZEMPIC (0.25 OR 0.5		UNIT/ML, 20000 UNIT/ML, 3000		SYMDEKO	53
MG/DOSE) SUBCUTANEOUS		UNIT/ML, 4000 UNIT/ML, 40000		SYNAGIS	29
SOLUTION PEN-INJECTOR 2		UNIT/ML	53	SYNAREL	56
MG/3ML	31	REVLIMID ORAL CAPSULE 10		<i>Tadalafil (PAH)</i>	57
OZEMPIC (1 MG/DOSE)		MG, 15 MG, 2.5 MG, 20 MG, 25		<i>Tadalafil Oral Tablet 2.5 MG, 5 MG</i> ..	57
SUBCUTANEOUS SOLUTION		MG, 5 MG	50	TAFINLAR ORAL CAPSULE	53
PEN-INJECTOR 4 MG/3ML	31	REVUFORJ	51	TALTZ SUBCUTANEOUS	
OZEMPIC (2 MG/DOSE)	31	REXULTI	18	SOLUTION AUTO-INJECTOR	8
<i>PAZOPanib HCl</i>	53	REZDIFFRA	29	TALTZ SUBCUTANEOUS	
PEGASYS SUBCUTANEOUS		<i>Ribavirin Oral Capsule</i>	53	SOLUTION PREFILLED SYRINGE	
SOLUTION 180 MCG/ML	53	<i>Ribavirin Oral Tablet 200 MG</i>	53	20 MG/0.25ML, 40 MG/0.5ML, 80	
PEGASYS SUBCUTANEOUS		RINVOQ	8	MG/ML	8
SOLUTION PREFILLED SYRINGE	53	<i>Rivastigmine</i>	28	TARGRETIN EXTERNAL	53
<i>Phenoxybenzamine HCl Oral</i>	18	<i>Rivastigmine Tartrate</i>	28	TASIGNA	29
<i>Pirfenidone Oral Tablet 267 MG,</i>		RIVFLOZA	29	<i>Tazarotene External Cream 0.1 %</i> ..	49
<i>801 MG</i>	67	ROZLYTREK	52	TAZORAC EXTERNAL CREAM	
PLEGRIDY INTRAMUSCULAR	42	RYBELSUS	31	0.05 %	49
PLEGRIDY STARTER PACK		RYDAPT	53	TAZORAC EXTERNAL GEL	49
SUBCUTANEOUS SOLUTION		SANCUSO	18	TEMODAR INTRAVENOUS	53
AUTO-INJECTOR	42	<i>Sapropterin Dihydrochloride Oral</i>		<i>Temozolomide</i>	53
PLEGRIDY STARTER PACK		<i>Packet</i>	53	<i>Teriparatide Subcutaneous</i>	
SUBCUTANEOUS SOLUTION		<i>Sapropterin Dihydrochloride Oral</i>		<i>Solution Pen-Injector 560</i>	
PREFILLED SYRINGE	42	<i>Tablet</i>	53	<i>MCG/2.24ML</i>	29
PLEGRIDY SUBCUTANEOUS		SAVELLA	18	<i>Testosterone Enanthate</i>	
SOLUTION AUTO-INJECTOR	42	SAVELLA TITRATION PACK	18	<i>Intramuscular Solution</i>	59
PLEGRIDY SUBCUTANEOUS		SIGNIFOR	53	<i>Testosterone Transdermal Gel 10</i>	
SOLUTION PREFILLED SYRINGE	42	<i>Sildenafil Citrate Intravenous</i>	53	<i>MG/ACT (2%), 25 MG/2.5GM (1%)</i> ..	58
POMALYST	53	<i>Sildenafil Citrate Oral Tablet 20 MG</i>	53	<i>Tetrabenazine Oral Tablet 12.5</i>	
<i>Potassium Chloride Oral Solution</i>		SIMPONI ARIA	53	<i>MG, 25 MG</i>	53
<i>20 MEQ/15ML (10%), 40</i>		SIMPONI SUBCUTANEOUS		THALOMID ORAL CAPSULE 100	
<i>MEQ/15ML (20%)</i>	18	SOLUTION AUTO-INJECTOR	53	MG, 50 MG	53
PRALUENT SUBCUTANEOUS		SIMPONI SUBCUTANEOUS		<i>Tobramycin Inhalation Nebulization</i>	
SOLUTION AUTO-INJECTOR	53	SOLUTION PREFILLED SYRINGE	53	<i>Solution 300 MG/4ML</i>	18
PROLASTIN-C INTRAVENOUS		SIRTURO ORAL TABLET 100 MG ..	18	<i>Tobramycin Inhalation Nebulization</i>	
SOLUTION	53	SKYRIZI INTRAVENOUS	8	<i>Solution 300 MG/5ML</i>	53
PROLIA SUBCUTANEOUS		SKYRIZI PEN	8	<i>Tolvaptan Oral Tablet</i>	53
SOLUTION PREFILLED SYRINGE	53	SKYRIZI SUBCUTANEOUS		TOVIAZ	65
PROMACTA ORAL TABLET 12.5		SOLUTION CARTRIDGE	8	<i>traMADol HCl ER Oral Tablet</i>	
MG, 25 MG, 50 MG, 75 MG	53	SKYRIZI SUBCUTANEOUS		<i>Extended Release 24 Hour 200</i>	
<i>Pyrimethamine Oral</i>	23	SOLUTION PREFILLED SYRINGE ..	8	<i>MG, 300 MG</i>	41
REBIF REBIDOSE		<i>Sodium Phenylbutyrate Oral</i>		TREMFYA CROHNS INDUCTION	
SUBCUTANEOUS SOLUTION		<i>Powder 3 GM/ITSP</i>	53	SUBCUTANEOUS SOLUTION	
AUTO-INJECTOR	53	<i>Sodium Phenylbutyrate Oral Tablet</i> ..	53	AUTO-INJECTOR 200 MG/2ML	8
REBIF REBIDOSE TITRATION		SOMATULINE DEPOT	53	TREMFYA INTRAVENOUS	8
PACK SUBCUTANEOUS		SOMAVERT	53	TREMFYA ONE-PRESS	8
SOLUTION AUTO-INJECTOR	53	<i>SORafenib Tosylate</i>	67	TREMFYA PEN	
REBIF SUBCUTANEOUS		SOVALDI	42	SUBCUTANEOUS SOLUTION	
SOLUTION PREFILLED SYRINGE	53	SPRYCEL ORAL TABLET 100		AUTO-INJECTOR 100 MG/ML,	
REBIF TITRATION PACK		MG, 140 MG, 20 MG, 50 MG, 70		200 MG/2ML	8
SUBCUTANEOUS SOLUTION		MG, 80 MG	53	TREMFYA SUBCUTANEOUS	
PREFILLED SYRINGE	53	STELARA INTRAVENOUS	8	SOLUTION PREFILLED SYRINGE	
REMICADE	65	STELARA SUBCUTANEOUS		100 MG/ML, 200 MG/2ML	8
REMODULIN INJECTION		SOLUTION 45 MG/0.5ML	8	<i>Tretinoin External</i>	49
SOLUTION 100 MG/20ML, 20		STELARA SUBCUTANEOUS		<i>Tretinoin Microsphere External Gel</i>	
MG/20ML, 200 MG/20ML, 50		SOLUTION PREFILLED SYRINGE		<i>0.1 %</i>	49
MG/20ML	53	45 MG/0.5ML, 90 MG/ML	8	<i>Tretinoin Microsphere Pump</i>	
RESTASIS	67	STIVARGA	53	<i>External Gel 0.04 %</i>	49
		SUCRAID	55		

TRIKAFTA ORAL TABLET	
THERAPY PACK	53
TRULICITY SUBCUTANEOUS	
SOLUTION AUTO-INJECTOR	31
TRUQAP ORAL TABLET 200 MG ..	29
TRYNGOLZA	60
TYMLOS	53
TYSABRI	53
TYVASO	53
TYVASO REFILL KIT	53
TYVASO STARTER KIT	53
UPTRAVI INTRAVENOUS	53
UPTRAVI ORAL TABLET 1000	
MCG, 1200 MCG, 1400 MCG,	
1600 MCG, 200 MCG, 400 MCG,	
600 MCG, 800 MCG	53
UPTRAVI TITRATION	53
VELSIPITY	29
VEMLIDY	18
VENCLEXTA ORAL TABLET 10	
MG, 100 MG, 50 MG	53
VENCLEXTA STARTING PACK	53
VENTAVIS	53
VERZENIO	65
<i>Vigabatrin</i>	53
VIIBRYD ORAL TABLET	61
<i>Vilazodone HCl</i>	61
VIMPAT INTRAVENOUS	18
VIMPAT ORAL SOLUTION	18
VIOKACE	48
VITRAKVI ORAL CAPSULE 100	
MG, 25 MG	53
VITRAKVI ORAL SOLUTION	53
VIVITROL	62
VOQUEZNA	63
<i>Voriconazole Oral</i>	4
VOSEVI	53
VOTRIENT	53
VUMERITY	53
WAINUA	29
WEGOVY	64
XALKORI ORAL CAPSULE	53
XELJANZ ORAL SOLUTION	8
XELJANZ ORAL TABLET	8
XELJANZ XR	8
XIFAXAN ORAL TABLET 200	
MG, 550 MG	66
XOLAIR SUBCUTANEOUS	
SOLUTION PREFILLED SYRINGE	
150 MG/ML, 75 MG/0.5ML	53
XOLAIR SUBCUTANEOUS	
SOLUTION RECONSTITUTED	53
XTANDI ORAL CAPSULE	53
XTANDI ORAL TABLET 40 MG,	
80 MG	65
ZELBORAF	53
ZENPEP ORAL CAPSULE	
DELAYED RELEASE PARTICLES	
10000-32000 UNIT, 15000-47000	
UNIT, 20000-63000 UNIT, 25000-	
79000 UNIT, 3000-10000 UNIT,	
40000-126000 UNIT, 5000-24000	
UNIT	48
ZEPATIER	42
ZEPBOUND SUBCUTANEOUS	
SOLUTION 10 MG/0.5ML, 2.5	
MG/0.5ML, 5 MG/0.5ML, 7.5	
MG/0.5ML	68
ZEPBOUND SUBCUTANEOUS	
SOLUTION AUTO-INJECTOR	68
ZEPOSIA	65
ZEPOSIA 7-DAY STARTER PACK	65
<i>Zoledronic Acid Intravenous</i>	
<i>Concentrate</i>	53
<i>Zoledronic Acid Intravenous</i>	
<i>Solution 5 MG/100ML</i>	53
ZOLINZA	53
ZYDELIG	53
ZYKADIA ORAL TABLET	53